Technology | 2020.05.13
Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19. Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a patent-pending, repurposed oral antiviral drug.
(PRWeb May 13, 2020)
Read the full story at https://www.prweb.com/releases/catalent_signs_development_agreement_with_ennaid_therapeutics_on_its_covid_19_lead_program/prweb17119113.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]lead_program/prweb17119113.htm
